SYSTEMATIC REVIEW article
Front. Oncol.
Sec. Gastrointestinal Cancers: Hepato Pancreatic Biliary Cancers
Efficacy and Safety of Sorafenib Combined with Transarterial Chemoembolization (TACE) in the Treatment of Hepatocellular Carcinoma:A Meta-Analysis of Randomized Controlled Trials
Provisionally accepted
- 1Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
- 2City University of Wuhan, Wuhan, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Objective: Transarterial chemoembolization (TACE) plus sorafenib has led to an increase in randomized controlled trials The efficacy and safety of sorafenib combined with TACE for the treatment of hepatocellular carcinoma (HCC) remain controversial. We conducted a comprehensive meta-analysis of randomized controlled trials on this issue. Methods: A literature search was conducted by using online database: PubMed, the Cochrane Library, Embase, Web of Science, Chinese National Knowledge Infrastructure (CNKI) and Wan-fang, with no language restrictions. A Meta-analysis was performed to calculate the pooled odds ratio (OR) and its corresponding 95% confidence interval (CI) for the efficacy and safety of sorafenib combined with TACE in the treatment of HCC. Review Manager 5.4 software was used for data analysis. Results: A total of 19 randomized controlled trials involving 2,029 patients met the inclusion criteria for this meta-analysis, including sorafenib combined with TACE group (n=1023) and TACE group (n=1006). The results of meta-analysis showed that sorafenib combined with TACE had a better prognosis in partial response rate (PR) [OR=1.58,95%CI (1.30,1.92), P<0.00001] with low heterogeneity among studies (P=0.67; I2=0%) and the objective response rate (ORR) [OR=1.93, 95%CI (1.59,2.34), P<0.00001] with low heterogeneity among studies (P=0.42; I2=3%). The 12-month overall survival (OS) was also significantly increased by combination therapy [OR=3.18, 95%CI (2.41,4.19), P<0.00001] . In terms of safety, the incidences were significantly high in TACE plus sorafenib group compared to TACE group for hand-foot skin reaction OR=4.48, 95%CI (3.28,6.13), P<0.00001 and for abdominal pain or diarrhea OR=3.10, 95%CI (2.24,4.29), P=0.04. However, no significant difference was found in nausea or vomit [OR=1.14,95%CI (0.81,1.59), P=0.68] or fever [OR=0.87, 95%CI (0.61,1.23), P=0.87]. Conclusion: The current comprehensive evidence suggests that sorafenib combined with TACE is more effective than TACE alone, especially for patients with intermediate-advanced and primary HCC.
Keywords: Hepatocellular Carcinoma, Sorafenib, Transarterial chemoembolization, randomized controlled trials, Meta-analysis
Received: 04 Jun 2025; Accepted: 27 Oct 2025.
Copyright: © 2025 Yu, Xiong, Liao, Deng and Zhai. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Xuejia Zhai, zhaixuejia@163.com
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.